Cargando…
Non–beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma
Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(–) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity. We investigated the effect of R(+) enantiomers of propranolol and atenolol on the formation of IH-like blo...
Autores principales: | Seebauer, Caroline T., Graus, Matthew S., Lan Huang, McCann, Alex, Wylie-Sears, Jill, Fontaine, Frank, Karnezis, Tara, Zurakowski, David, Staffa, Steven J., Meunier, Frédéric, Mulliken, John B., Bischoff, Joyce, Francois, Mathias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803322/ https://www.ncbi.nlm.nih.gov/pubmed/34874911 http://dx.doi.org/10.1172/JCI151109 |
Ejemplares similares
-
A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas
por: Zhao, Ze-Liang, et al.
Publicado: (2021) -
Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health
por: Hermans, Mireille M., et al.
Publicado: (2023) -
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma
por: Hermans, Mireille M., et al.
Publicado: (2022) -
Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma
por: Hermans, Mireille M., et al.
Publicado: (2023) -
Oral Atenolol versus Propranolol in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis
por: Pattanshetti, Swapnil Annasaheb, et al.
Publicado: (2022)